OptimizeRx CEO, William Febbo, to Speak at the Bank of America Annual HCIT and Digital Health Conference

ROCHESTER, Mich., Feb. 07, 2022 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX),  a leading provider of point-of-care technology solutions helping patients start and stay on therapy, announced today that Will Febbo, OptimizeRx’s CEO, will participate in the upcoming Bank of America’s Annual HCIT and Digital Health Conference on February 23, 2022.

Mr. Febbo will join a panel of speakers to discuss, “Tech-Enabled Rx Solutions,” on February 23rd from 11:15 AM ET – 12:00 PM ET. The panel will be moderated by Rajat Bhatia, a Director with BofA Securities’ Global Healthcare Investment Banking team.

Event attendees will include healthcare-focused Bank of America corporate and commercial clients, executives from healthcare services and digital health companies, as well as private equity, venture capital and crossover equity investors.

About OptimizeRx
OptimizeRx is the best-in-class health technology company enabling care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. Connecting over 60% of U.S. healthcare providers and millions of their patients through a technology platform embedded within a proprietary point-of-care network, OptimizeRx helps patients start and stay on their medications. 

For more information, follow the company on Twitter, LinkedIn or visit www.optimizerx.com. 

Important Cautions Regarding Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates”, “believes”, “estimates”, “expects”, “forecasts”, “intends”, “plans”, “projects”, “targets”, “designed”, “could”, “may”, “should”, “will” or other similar words and expressions are intended to identify these forward-looking statements. All statements that reflect the Company’s expectations, assumptions, projections, beliefs or opinions about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements relating to the Company’s growth, business plans and future performance. These forward-looking statements are based on the Company’s current expectations and assumptions regarding the Company’s business, the economy, and other future conditions. The Company disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise, except as required by applicable law. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition, and other risks summarized in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020, its subsequent Quarterly Reports on Form 10-Q, and its other filings with the Securities and Exchange Commission.

OptimizeRx Contact 

Andy D’Silva, SVP Corporate Finance
adsilva@optimizerx.com

Media Relations Contact 
Maira Alejandra, Media Relations Manager 
malejandra@optimizerx.com

Investor Relations Contact
Ashley Robinson
LifeSci Advisors, LLC
arr@lifesciadvisors.com 

Source: OptimizeRx Corporation